Top

BMC Medicine

Published in:

01-12-2022 | Targeted Therapy | Research article

Risk and benefit for umbrella trials in oncology: a systematic review and meta-analysis

Authors: Karolina Strzebonska, Mateusz Blukacz, Mateusz T. Wasylewski, Maciej Polak, Bishal Gyawali, Marcin Waligora

Published in: BMC Medicine | Issue 1/2022

Abstract

Background

Umbrella clinical trials in precision oncology are designed to tailor therapies to the specific genetic changes within a tumor. Little is known about the risk/benefit ratio for umbrella clinical trials. The aim of our systematic review with meta-analysis was to evaluate the efficacy and safety profiles in cancer umbrella trials testing targeted drugs or a combination of targeted therapy with chemotherapy.

Methods

Our study was prospectively registered in PROSPERO (CRD42020171494). We searched Embase and PubMed for cancer umbrella trials testing targeted agents or a combination of targeted therapies with chemotherapy. We included solid tumor studies published between 1 January 2006 and 7 October 2019. We measured the risk using drug-related grade 3 or higher adverse events (AEs), and the benefit by objective response rate (ORR), progression-free survival (PFS), and overall survival (OS). When possible, data were meta-analyzed.

Results

Of the 6207 records identified, we included 31 sub-trials or arms of nine umbrella trials (N = 1637). The pooled overall ORR was 17.7% (95% confidence interval [CI] 9.5–25.9). The ORR for targeted therapies in the experimental arms was significantly lower than the ORR for a combination of targeted therapy drugs with chemotherapy: 13.3% vs 39.0%; p = 0.005. The median PFS was 2.4 months (95% CI 1.9–2.9), and the median OS was 7.1 months (95% CI 6.1–8.4). The overall drug-related death rate (drug-related grade 5 AEs rate) was 0.8% (95% CI 0.3–1.4), and the average drug-related grade 3/4 AE rate per person was 0.45 (95% CI 0.40–0.50).

Conclusions

Our findings suggest that, on average, one in five cancer patients in umbrella trials published between 1 January 2006 and 7 October 2019 responded to a given therapy, while one in 125 died due to drug toxicity. Our findings do not support the expectation of increased patient benefit in cancer umbrella trials. Further studies should investigate whether umbrella trial design and the precision oncology approach improve patient outcomes.

Available only for authorised users

Senft D, Leiserson MDM, Ruppin E, Ronai ZA. Precision oncology: the road ahead. Trends Mol Med. 2017;23(10):874–98. https://doi.org/10.1016/j.molmed.2017.08.003.CrossRefPubMedPubMedCentral

Siden EG, Park JJH, Zoratti MJ, Dron L, Harari O, Thorlund K, et al. Reporting of master protocols towards a standardized approach: a systematic review. Contemp Clin Trials Commun. 2019;15:100406. https://doi.org/10.1016/j.conctc.2019.100406.CrossRefPubMedPubMedCentral

Park JJH, Hsu G, Siden EG, Thorlund K, Mills EJ. An overview of precision oncology basket and umbrella trials for clinicians. CA Cancer J Clin. 2020;70(2):125–37. https://doi.org/10.3322/caac.21600.CrossRefPubMedPubMedCentral

American Society of Clinical Oncology Research Community Forum. Library of resources: conducting and managing cancer clinical trials. Alexandria: American Society of Clinical Oncology; 2020. https://www.asco.org/sites/new-www.asco.org/files/content-files/research-and-progress/documents/2020-ASCO-RCF-Library-Methodology.pdf. Accessed 3 Dec 2021

U. S Department of Health and Human Services Food and Drug Administration, master protocols: efficient clinical trial design strategies to expedite development of oncology drugs and biologics guidance for industry (Draft Guidance) 2018. https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM621817.pdf. Accessed 3 Dec 2021.

West HJ. Novel precision medicine trial designs. JAMA Oncol. 2017;3(3):423. https://doi.org/10.1001/jamaoncol.2016.5299.CrossRefPubMed

Renfro LA, Mandrekar SJ. Definitions and statistical properties of master protocols for personalized medicine in oncology. J Biopharm Stat. 2018;28(2):217–28. https://doi.org/10.1080/10543406.2017.1372778.CrossRefPubMed

Strzebonska K, Waligora M. Umbrella and basket trials in oncology: ethical challenges. BMC Med Ethics. 2019;20(1):58. https://doi.org/10.1186/s12910-019-0395-5.CrossRefPubMedPubMedCentral

Woodcock J, LaVange LM. Master protocols to study multiple therapies, multiple diseases, or both. N Engl J Med. 2017;377(1):62–70. https://doi.org/10.1056/NEJMra1510062.CrossRefPubMed

10.

Waligora M, Strzebonska K. Umbrella trials design. In: Frey B, editor. The SAGE encyclopedia of research design. USA: SAGE Publications, Inc; 2022. p. 1763–4. https://doi.org/10.4135/9781071812082.n657.

11.

Bogin V. Master protocols: new directions in drug discovery. Contemp Clin Trials Commun. 2020;18:100568. https://doi.org/10.1016/j.conctc.2020.100568.CrossRefPubMedPubMedCentral

12.

Verweij J, Hendriks HR, Zwierzina H. Innovation in oncology clinical trial design. Cancer Treat Rev. 2019;74:15–20. https://doi.org/10.1016/j.ctrv.2019.01.001.CrossRefPubMed

13.

Renfro LA, Sargent DJ. Statistical controversies in clinical research: basket trials, umbrella trials, and other master protocols: a review and examples. Ann Oncol. 2017;28(1):34–43. https://doi.org/10.1093/annonc/mdw413.CrossRefPubMed

14.

National Cancer Institute. NCI Dictionaries. Dictionary of cancer terms. Umbrella trial. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/umbrella-trial. Accessed 3 Dec 2021.

15.

Prasad V. Perspective: the precision-oncology illusion. Nature. 2016;537(7619):S63. https://doi.org/10.1038/537S63a.CrossRefPubMed

16.

Tannock IF, Hickman JA. Limits to personalized cancer medicine. N Engl J Med. 2016;375(13):1289–94. https://doi.org/10.1056/NEJMsb1607705.CrossRefPubMed

17.

Voest EE, Bernards R. DNA-guided precision medicine for cancer: a case of irrational exuberance? Cancer Discov. 2016;6(2):130–2. https://doi.org/10.1158/2159-8290.CD-15-1321.CrossRefPubMed

18.

Kimmelman J, Tannock I. The paradox of precision medicine. Nat Rev Clin Oncol. 2018;15(6):341–2. https://doi.org/10.1038/s41571-018-0016-0.CrossRefPubMed

19.

Park JJH, Siden E, Zoratti MJ, Dron L, Harari O, Singer J, et al. Systematic review of basket trials, umbrella trials, and platform trials: a landscape analysis of master protocols. Trials. 2019;20(1):572. https://doi.org/10.1186/s13063-019-3664-1.CrossRefPubMedPubMedCentral

20.

Collignon O, Gartner C, Haidich AB, Hemmings RJ, Hofner B, Pétavy F, et al. Current statistical considerations and regulatory perspectives on the planning of confirmatory basket, umbrella, and platform trials. Clin Pharmacol Ther. 2020;107(5):1059–67. https://doi.org/10.1002/cpt.1804.CrossRefPubMed

21.

Hey SP, Weijer C, Taljaard M, Kesselheim AS. Research ethics for emerging trial designs: does equipoise need to adapt? BMJ. 2018;360:k226. https://doi.org/10.1136/bmj.k226.CrossRefPubMed

22.

International Ethical Guidelines for Health-related Research Involving Humans, Fourth Edition. Geneva: Council for International Organizations of Medical Sciences (CIOMS); 2016. https://cioms.ch/wp-content/uploads/2017/01/WEB-CIOMS-EthicalGuidelines.pdf. Accessed 7 Jun 2022.

23.

Rid A, Wendler D. A framework for risk-benefit evaluations in biomedical research. Kennedy Inst Ethics J. 2011;21(2):141–79. https://doi.org/10.1353/ken.2011.0007.CrossRefPubMed

24.

Weijer C, Miller PB. When are research risks reasonable in relation to anticipated benefits? Nat Med. 2004;10(6):570–3. https://doi.org/10.1038/nm0604-570.CrossRefPubMed

25.

Wendler D, Miller FG. Assessing research risks systematically: the net risks test. J Med Ethics. 2007;33(8):481–6. https://doi.org/10.1136/jme.2005.014043.CrossRefPubMedPubMedCentral

26.

Waligora M, Bala MM, Koperny M, Wasylewski MT, Strzebonska K, Jaeschke R, et al. Risk and surrogate benefit for pediatric phase I trials in oncology: a systematic review with meta-analysis. PLoS Med. 2018;15(2):e1002505. https://doi.org/10.1371/journal.pmed.1002505.CrossRefPubMedPubMedCentral

27.

Schwaederle M, Zhao M, Lee JJ, Eggermont AM, Schilsky RL, Mendelsohn J, et al. Impact of precision medicine in diverse cancers: a meta-analysis of phase II clinical trials. J Clin Oncol. 2015;33(32):3817–25. https://doi.org/10.1200/JCO.2015.61.5997.CrossRefPubMedPubMedCentral

28.

Magee DE, Hird AE, Klaassen Z, Sridhar SS, Nam RK, Wallis CJD, et al. Adverse event profile for immunotherapy agents compared with chemotherapy in solid organ tumors: a systematic review and meta-analysis of randomized clinical trials. Ann Oncol. 2020;31(1):50–60. https://doi.org/10.1016/j.annonc.2019.10.008.CrossRefPubMed

29.

Mackley MP, Fernandez NR, Fletcher B, Woolcott CG, Fernandez CV. Revisiting risk and benefit in early oncology trials in the era of precision medicine: a systematic review and meta-analysis of phase I trials of targeted single-agent anticancer therapies. JCO Precis Oncol. 2021;5:17–26. https://doi.org/10.1200/PO.20.00214.CrossRefPubMed

30.

Strzebonska K, Wasylewski MT, Zaborowska L, Polak M, Slugocka E, Stras J, et al. Risk and benefit for targeted therapy agents in pediatric phase II trials in oncology: a systematic review with a meta-analysis. Target Oncol. 2021;16(4):415–24. https://doi.org/10.1007/s11523-021-00822-5.CrossRefPubMedPubMedCentral

31.

Bedard PL, Hyman DM, Davis MS, Siu LL. Small molecules, big impact: 20 years of targeted therapy in oncology. Lancet. 2020;395(10229):1078–88. https://doi.org/10.1016/S0140-6736(20)30164-1.CrossRefPubMed

32.

Azam F, Vazquez A. Trends in phase II trials for cancer therapies. Cancers (Basel). 2021;13(2):178. https://doi.org/10.3390/cancers13020178.CrossRef

33.

Le Tourneau C, Belin L, Paoletti X, Biéche I, Kamal M. Precision medicine: lessons learned from the SHIVA trial – author’s reply. Lancet Oncol. 2015;16(16):e581–2. https://doi.org/10.1016/S1470-2045(15)00455-6.CrossRefPubMed

34.

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https://doi.org/10.1136/bmj.n71.CrossRefPubMedPubMedCentral

35.

Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021;372:n160. https://doi.org/10.1136/bmj.n160.CrossRefPubMedPubMedCentral

36.

Strzebonska K, Wasylewski M, Blukacz M, Gyawali B, Waligora M. Risk and benefit for umbrella trials in oncology: a systematic review with meta-analysis: PROSPERO; 2020. https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42020171494. Accessed 3 Dec 2021

37.

Karp DD, Falchook GS. Handbook of targeted cancer therapy and immunotherapy. Targeted cancer therapy. 2nd ed. Philadelphia: Wolters Kluwer; 2018.

38.

Canadian Agency for Drugs and Technologies in Health. CADTH peer review checklist for search strategies. Ottawa: The Agency; 2013. https://www.cadth.ca/sites/default/files/is/Peer_review/CADTH%20Peer%20Review%20Checklist%20for%20Search%20Strategies_e.pdf. Accessed 3 Dec 2021

39.

National Cancer Institute. Common Terminology Criteria for Adverse Events: (CTCAE). https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm. Accessed 3 Dec 2021.

40.

Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomized trials. BMJ. 2019;366:l4898. https://doi.org/10.1136/bmj.l4898.CrossRefPubMed

41.

Sterne JAC, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomized studies of interventions. BMJ. 2016;355:i4919. https://doi.org/10.1136/bmj.i4919.CrossRefPubMedPubMedCentral

42.

Carpenter J, Bithell J. Bootstrap confidence intervals: when, which, what? A practical guide for medical statisticians. Stat Med. 2000;19(9):1141–64 https://doi.org/10.1002/(sici)1097-0258(20000515)19:9<1141::aid-sim479>3.0.co;2-f.CrossRef

43.

Kim ES, Herbst RS, Wistuba II, Lee JJ, Blumenschein GR Jr, Tsao A, et al. The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov. 2011;1(1):44–53. https://doi.org/10.1158/2159-8274.CD-10-0010.CrossRefPubMedPubMedCentral

44.

Tsao AS, Liu S, Lee JJ, Alden C, Blumenschein G, Herbst R, et al. Clinical outcomes and biomarker profiles of elderly pretreated NSCLC patients from the BATTLE trial. J Thorac Oncol. 2012;7(11):1645–52. https://doi.org/10.1097/JTO.0b013e31826910ff.CrossRefPubMedPubMedCentral

45.

Blumenschein GR Jr, Saintigny P, Liu S, Kim ES, Tsao AS, Herbst RS, et al. Comprehensive biomarker analysis and final efficacy results of sorafenib in the BATTLE trial. Clin Cancer Res. 2013;19(24):6967–75. https://doi.org/10.1158/1078-0432.CCR-12-1818.CrossRefPubMedPubMedCentral

46.

Herbst RS, Blumenschein GR Jr, Kim ES, Lee J, Tsao AS, Alden CM, et al. Sorafenib treatment efficacy and KRAS biomarker status in the Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) trial. J Clin Oncol. 2010;28(15_suppl):7609. https://doi.org/10.1200/jco.2010.28.15_suppl.7609.CrossRef

47.

Tsao AS, Liu S, Lee JJ, Alden CM, Blumenschein GR Jr, Herbst R, et al. Clinical and biomarker outcomes of the phase II vandetanib study from the BATTLE trial. J Thorac Oncol. 2013;8(5):658–61. https://doi.org/10.1097/JTO.0b013e31828d08ae.CrossRefPubMedPubMedCentral

48.

Papadimitrakopoulou V, Lee JJ, Wistuba II, Tsao AS, Fossella FV, Kalhor N, et al. The BATTLE-2 Study: a biomarker-integrated targeted therapy study in previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol. 2016;34(30):3638–47. https://doi.org/10.1200/JCO.2015.66.0084.CrossRefPubMedPubMedCentral

49.

Papadimitrakopoulou V, Lee JJ, Wistuba II, Tsao AS, Fossella FV, Heymach J, et al. BATTLE-2: KRAS mutation and outcome in a biomarker-integrated study in previously treated patients (pts) with advanced non-small cell lung cancer (NSCLC). J Clin Oncol. 2014;32(15_suppl):8042. https://doi.org/10.1200/jco.2014.32.15_suppl.8042.CrossRef

50.

Zhou Q, Zhang XC, Tu HY, Gan B, Wang BC, Xu CR, et al. Biomarker-integrated study of single agent targeting molecular alterations of PI3KCA, MET, ALK, ROS1, KRAS, NRAS or BRAF in advanced NSCLC: phase 2 umbrella trial in China (CTONG1505). Ann Oncol. 2018;29(9_suppl):ix113. https://doi.org/10.1093/annonc/mdy441.CrossRef

51.

Wu Y, Zhou Q, Zhang X, Tu H, Gan B, Wang B, et al. P1. 01-97 cluster trial: Ph2 biomarker-integrated study of single agent alpelisib, capmatinib, ceritinib and binimetinib in advNSCLC. J Thorac Oncol. 2018;13(10):S500–1. https://doi.org/10.1016/j.jtho.2018.08.653.CrossRef

52.

Adams RA, Brown E, Brown L, Butler R, Falk S, Fisher D, et al. FOCUS4-D: results from a randomised, placebo controlled trial (RCT) of AZD8931 (an inhibitor of signalling by HER1, 2, and 3) in patients (pts) with advanced or metastatic colorectal cancer (aCRC) in tumours that are wildtype (wt) for BRAF, PIK3CA, KRAS & NRAS. Ann Oncol. 2016;27(6_suppl):vi168. https://doi.org/10.1093/annonc/mdw370.57.CrossRef

53.

Richman SD, Adams R, Brown E, Brown L, Butler R, Falk S, et al. FOCUS4: MAMS trial design in action. Early closure of FOCUS4-D (Pan-HER 1, 2 and 3 inhibitor versus placebo) in advanced colorectal cancer (aCRC) patients, with tumours wildtype (WT) for KRAS, NRAS, BRAF and PIK3CA. J Pathol. 2017;243(S1):S13.

54.

Adams R, Brown E, Brown L, Butler R, Falk S, Fisher D, et al. Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2–3 randomised trial. Lancet Gastroenterol Hepatol. 2018;3(3):162–71. https://doi.org/10.1016/S2468-1253(17)30394-1.CrossRefPubMed

55.

Herbst R, Redman M, Gandara DR, Hirsch FR, Mack P, Borghaei H, et al. OA 14.07 progress in lung squamous cell carcinoma from the Lung-MAP Master Protocol (S1400) sub-studies S1400A, S1400B, S1400C and S1400D. J Thorac Oncol. 2017;12(11):S1783–4. https://doi.org/10.1016/j.jtho.2017.09.412.CrossRef

56.

Wade JL, Langer CJ, Redman M, Aggarwal C, Bradley JD, Crawford J, et al. A phase II study of GDC-0032 (taselisib) for previously treated PI3K positive patients with stage IV squamous cell lung cancer (SqNSCLC): LUNG-MAP sub-study SWOG S1400B. J Clin Oncol. 2017;35(15_suppl):9054. https://doi.org/10.1200/JCO.2017.35.15_suppl.9054.CrossRef

57.

Langer CJ, Redman MW, Wade JL 3rd, Aggarwal C, Bradley JD, Crawford J, et al. SWOG S1400B (NCT02785913), a phase II study of GDC-0032 (taselisib) for previously treated PI3K-positive patients with stage IV squamous cell lung cancer (Lung-MAP Sub-Study). J Thorac Oncol. 2019;14(10):1839–46. https://doi.org/10.1016/j.jtho.2019.05.029.CrossRefPubMedPubMedCentral

58.

Edelman MJ, Redman MW, Albain KS, McGary EC, Rafique N, Petro DP, et al. A phase II study of palbociclib (P) for previously treated cell cycle gene alteration positive patients (pts) with stage IV squamous cell lung cancer (SCC): Lung-MAP sub-study SWOG S1400C. J Clin Oncol. 2017;35(15_suppl):9056. https://doi.org/10.1200/JCO.2017.35.15_suppl.9056.CrossRef

59.

Edelman MJ, Redman MW, Albain KS, McGary EC, Rafique NM, Petro D, et al. SWOG S1400C (NCT02154490) - a phase II study of palbociclib for previously treated cell cycle gene alteration–positive patients with stage IV squamous cell lung cancer (Lung-MAP Substudy). J Thorac Oncol. 2019;14(10):1853–9. https://doi.org/10.1016/j.jtho.2019.06.027.CrossRefPubMedPubMedCentral

60.

Aggarwal C, Redman MW, Lara P, Borghaei H, Hoffman PC, Bradley JD, et al. Phase II study of the FGFR inhibitor AZD4547 in previously treated patients with FGF pathway-activated stage IV squamous cell lung cancer (SqNSCLC): LUNG-MAP sub-study SWOG S1400D. J Clin Oncol. 2017;35(15_suppl):9055. https://doi.org/10.1200/JCO.2017.35.15_suppl.9055.CrossRef

61.

Aggarwal C, Redman MW, Lara PN Jr, Borghaei H, Hoffman P, Bradley JD, et al. SWOG S1400D (NCT02965378), a phase II study of the fibroblast growth factor receptor inhibitor AZD4547 in previously treated patients with fibroblast growth factor pathway–activated stage IV squamous cell lung cancer (Lung-MAP Substudy). J Thorac Oncol. 2019;14(10):1847–52. https://doi.org/10.1016/j.jtho.2019.05.041.CrossRefPubMedPubMedCentral

62.

Owonikoko TK, Redman MW, Byers LA, Hirsch FR, Mack PC, Schwartz LH, et al. A phase II study of talazoparib (BMN 673) in patients with homologous recombination repair deficiency (HRRD) positive stage IV squamous cell lung cancer (Lung-MAP Sub-Study, S1400G). J Clin Oncol. 2019;37:15_suppl–9022. https://doi.org/10.1200/JCO.2019.37.15_suppl.9022.CrossRef

63.

Waqar SN, Redman MW, Arnold SM, Hirsch FR, Mack PC, Schwartz LH, et al. Phase II study of ABBV-399 (process II) in patients with C-MET positive stage IV/recurrent lung squamous cell cancer (SCC): LUNG-MAP sub-study S1400K (NCT03574753). J Clin Oncol. 2019;37:15_suppl–9075. https://doi.org/10.1200/JCO.2019.37.15_suppl.9075.CrossRef

64.

Seymour MT, Brown SR, Middleton G, Maughan T, Richman S, Gwyther S, et al. Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial. Lancet Oncol. 2013;14(8):749–59. https://doi.org/10.1016/S1470-2045(13)70163-3.CrossRefPubMedPubMedCentral

65.

Park S, Shim J, Jung HA, Sun JM, Lee SH, Park WY, et al. Biomarker driven phase II umbrella trial study of AZD1775, AZD2014, AZD2811 monotherapy in relapsed small cell lung cancer. J Clin Oncol. 2019;37(15_suppl):8514. https://doi.org/10.1200/JCO.2019.37.15_suppl.8514.CrossRef

66.

Pivot X, Poole C, Martín M, Gligorov J, Barrios CH, Vrdoljak E, et al. The open-label, multinational, multicenter, phase IIIB umbrella study of subcutaneous trastuzumab with or without chemotherapy or pertuzumab in patients (pts) with HER2-positive early breast cancer (EBC) or metastatic breast cancer (MBC): pooled analysis of safety data from the UmbHER1 program. Eur J Cancer. 2018;92(Suppl. 3):S105–6.CrossRef

67.

Pivot X, Poole C, Martín M, Gligorov J, Barrios CH, Vrdoljak E, et al. An open-label, multinational, multicentre, phase IIIB umbrella study of subcutaneous trastuzumab with or without chemotherapy or pertuzumab in patients with HER2-positive early or metastatic breast cancer (UmbHER1): interim safety results from early breast cancer studies. Ann Oncol. 2016;27:6_suppl–vi63. https://doi.org/10.1093/annonc/mdw364.66.CrossRef

68.

Zambetti M, Montemurro F, Morandi P, Zamagni C, Brandes AA, Bisagni G, et al. Safety profile of subcutaneous trastuzumab for the treatment of patients with HER2-positive early or locally advanced breast cancer: primary analysis of the SCHEARLY study. Eur J Cancer. 2018;105:61–70. https://doi.org/10.1016/j.ejca.2018.09.034.CrossRefPubMed

69.

Woodward N, De Boer RH, Redfern A, White M, Young J, Truman M, et al. Results from the first multicenter, open-label, phase IIIb study investigating the combination of pertuzumab with subcutaneous trastuzumab and a taxane in patients with HER2-positive metastatic breast cancer (SAPPHIRE). Clin Breast Cancer. 2019;19(3):216–24. https://doi.org/10.1016/j.clbc.2019.02.008.CrossRefPubMed

70.

Lee J, Kim ST, Kozarewa I, Kim HK, Kim K, Mortimer PG, et al. Selumetinib plus docetaxel as second-line chemotherapy in KRAS mutant, KRAS amplified or MEK signatured gastric cancer patients: first arm of the umbrella trial in GC though the molecular screening, VIKTORY trial. J Clin Oncol. 2018;36:15_suppl–4061. https://doi.org/10.1200/JCO.2018.36.15_suppl.4061.CrossRef

71.

Lee J, Kim ST, Kim K, Lee H, Kozarewa I, Mortimer PGS, et al. Tumor genomic profiling guides patients with metastatic gastric cancer to targeted treatment: the VIKTORY Umbrella Trial. Cancer Discov. 2019;9(10):1388–405. https://doi.org/10.1158/2159-8290.CD-19-0442.CrossRefPubMed

72.

Strzebonska K, Blukacz M, Wasylewski MT, Polak M, Gyawali B, Waligora M. Raw data file for risk and benefit for umbrella trials in oncology: a systematic review and meta-analysis. 2022. The Open Science Framework, https://osf.io/cx2vh/.

73.

Hazim A, Prasad V. A pooled analysis of published, basket trials in cancer medicine. Eur J Cancer. 2018;101:244–50. https://doi.org/10.1016/j.ejca.2018.06.035.CrossRefPubMed

74.

Wasylewski MT, Strzebonska K, Koperny M, Polak M, Kimmelman J, Waligora M. Clinical development success rates and social value of pediatric phase 1 trials in oncology. PLoS One. 2020;15(6):e0234911. https://doi.org/10.1371/journal.pone.0234911.CrossRefPubMedPubMedCentral

75.

Booth CM, Eisenhauer EA. Progression-free survival: meaningful or simply measurable? J Clin Oncol. 2012;30(10):1030–3. https://doi.org/10.1200/JCO.2011.38.7571.CrossRefPubMed

76.

Kovic B, Jin X, Kennedy SA, Hylands M, Pędziwiatr M, Kuriyama A, et al. Evaluating progression-free survival as a surrogate outcome for health-related quality of life in oncology: a systematic review and quantitative analysis. JAMA Intern Med. 2018;178(12):1586–96. https://doi.org/10.1001/jamainternmed.2018.4710.CrossRefPubMedPubMedCentral

77.

Gyawali B, Hey SP, Kesselheim AS. Evaluating the evidence behind the surrogate measures included in the FDA’s table of surrogate endpoints as supporting approval of cancer drugs. EClinicalMedicine. 2020;21:100332. https://doi.org/10.1016/j.eclinm.2020.100332.CrossRefPubMedPubMedCentral

78.

Hwang TJ, Gyawali B. Association between progression-free survival and patients’ quality of life in cancer clinical trials. Int J Cancer. 2019;144(7):1746–51. https://doi.org/10.1002/ijc.31957.CrossRefPubMed

79.

Gyawali B. Point: the imprecise pursuit of precision medicine: are biomarkers to blame? J Natl Compr Canc Netw. 2017;15(7):859–62. https://doi.org/10.6004/jnccn/2017.0126.CrossRefPubMed

80.

Cohen JW, Akshintala S, Kane E, Gnanapragasam H, Widemann BC, Steinberg SM, et al. A systematic review of pediatric phase I trials in oncology: toxicity and outcomes in the era of targeted therapies. Oncologist. 2020;25(6):532–40. https://doi.org/10.1634/theoncologist.2019-0615.CrossRefPubMedPubMedCentral

81.

Kaiser J. Is genome-guided cancer treatment hyped? Science. 2018;360(6387):365. https://doi.org/10.1126/science.360.6387.365.CrossRefPubMed

82.

Samuel JN, Booth CM, Eisenhauer E, Brundage M, Berry SR, Gyawali B. Association of quality-of-life outcomes in cancer drug trials with survival outcomes and drug class. JAMA Oncol. 2022:e220864. https://doi.org/10.1001/jamaoncol.2022.0864.

Title: Risk and benefit for umbrella trials in oncology: a systematic review and meta-analysis
Authors: Karolina Strzebonska
Mateusz Blukacz
Mateusz T. Wasylewski
Maciej Polak
Bishal Gyawali
Marcin Waligora
Publication date: 01-12-2022
Publisher: BioMed Central
Keywords: Targeted Therapy
Cytostatic Therapy
Published in: BMC Medicine / Issue 1/2022
Electronic ISSN: 1741-7015
DOI: https://doi.org/10.1186/s12916-022-02420-2

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Risk and benefit for umbrella trials in oncology: a systematic review and meta-analysis

Abstract

Background

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2022

Association between CYP metabolizer phenotypes and selective serotonin reuptake inhibitors induced weight gain: a retrospective cohort study

The risk of all-cause and cause-specific mortality in people prescribed mirtazapine: an active comparator cohort study using electronic health records

The duration of protection against clinical malaria provided by the combination of seasonal RTS,S/AS01E vaccination and seasonal malaria chemoprevention versus either intervention given alone

Effectiveness of rectal artesunate as pre-referral treatment for severe malaria in children under 5 years of age: a multi-country observational study

Investigation of the causal relationship between ALS and autoimmune disorders: a Mendelian randomization study

The transfer of maternal antibodies and dynamics of maternal and natural infection-induced antibodies against coxsackievirus A16 in Chinese children 0–13 years of age: a longitudinal cohort study